Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03006328 · ClinicalTrials.gov registry record · NA
The GEM (Goals for Eating and Moving) Study
A NA study of Obesity and Weight Gain, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 489
- Enrollment target
- 1
- Study location
NCT03006328: Completed NA study of Obesity and Weight Gain, sponsored by NYU Langone Health.
NCT03006328 is a NA study of Obesity and Weight Gain that has completed, run by NYU Langone Health. The registered enrollment target is 489 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (40% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03006328, a NA study of Obesity and Weight Gain, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 489 participants
- Enrollment target
- 1
- Study location
Study Summary
The GEM intervention leverages the patient-centered medical home model by using the GEM tool to provide individually tailored, patient-centered care, promote standardized weight management counseling by health coaches and primary team members, coordinate care between teams and other weight management service providers/programs (e.g., dietitians, health educators, DPP), and provide feedback to the provider and primary care team about patients' weight management-related goals, progress, and care.
Conditions Studied
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL GEM
Study Locations (1)
New York
- New York University Medical Center Institutional Review Boards - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 489 participants |
| Start Date | 2017-11-20 |
| Est. Completion | 2022-02-22 |
| Phase | NA |
What the finished NCT03006328 record still lists
NCT03006328 is an interventional study that assigns participants to a tested intervention. The registered 489 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (40% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Enhanced Usual Care is the first listed.
NCT03006328 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03006328 about?
NCT03006328 is a clinical study titled "The GEM (Goals for Eating and Moving) Study". The GEM intervention leverages the patient-centered medical home model by using the GEM tool to provide individually tailored, patient-centered care, promote standardized weight management counseling by health coaches and primary team members, coordinate care between teams and other weight managemen...
What is the current status of trial NCT03006328?
This trial is currently completed. It is a NA study. The enrollment target is 489 participants. The study started on 2017-11-20. Estimated completion is 2022-02-22.
What conditions does trial NCT03006328 study?
This clinical trial studies the following conditions: Obesity, Weight Gain.
What interventions are being tested in trial NCT03006328?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), GEM (BEHAVIORAL).
Who is sponsoring clinical trial NCT03006328?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03006328 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03006328's enrollment target sits among peer trials
489 145th of 1053 higher than 909 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Tai Chi as a Novel Strategy to Increase Physical Activity Among Adults Pursuing Metabolic and Bariatric Surgery
RECRUITING · NA
-
Mechanistic and Clinical Outcomes of a Surgical Innovation Aimed at Minimizing GERD Associated With VSG (INNOVATE-VSG)
RECRUITING · NA
-
SMARTer Weight Loss Management
RECRUITING · NA
-
HealthyTogether: RCT of a Dyadic Weight Management Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI